298 related articles for article (PubMed ID: 27994334)
1. Dual-Time
Ozen A; Altinay S; Ekmekcioglu O; Albayrak R; Muhammedoglu A; Yigitbas H; Bastug E; Celik A
Indian J Surg; 2016 Oct; 78(5):382-389. PubMed ID: 27994334
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
3. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
4. The Effects of Preoperative (18)F-FDG PET/CT in Breast Cancer Patients in Comparison to the Conventional Imaging Study.
Choi YJ; Shin YD; Kang YH; Lee MS; Lee MK; Cho BS; Kang YJ; Park JS
J Breast Cancer; 2012 Dec; 15(4):441-8. PubMed ID: 23346174
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorodeoxyglucose PET/computed tomography in locoregional staging and assessment of biological and clinical aggressiveness of breast cancer subtypes.
Ozkan EE; Sengul SS; Erdogan M; Gurdal O; Eroglu HE
Nucl Med Commun; 2019 Oct; 40(10):1043-1050. PubMed ID: 31425343
[TBL] [Abstract][Full Text] [Related]
7. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Breast MRI and (18)F-FDG PET/CT for the Preoperative Staging of Invasive Lobular Carcinoma versus Ductal Carcinoma.
Jung NY; Kim SH; Kim SH; Seo YY; Oh JK; Choi HS; You WJ
J Breast Cancer; 2015 Mar; 18(1):63-72. PubMed ID: 25834613
[TBL] [Abstract][Full Text] [Related]
10. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
12. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
[TBL] [Abstract][Full Text] [Related]
13. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
14. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Histopathological Features of Early-stage Invasive Ductal Breast Carcinoma by
Erol M; Önner H; Eren Karanis Mİ
Mol Imaging Radionucl Ther; 2021 Oct; 30(3):129-136. PubMed ID: 34658227
[TBL] [Abstract][Full Text] [Related]
17. Additional value of F-18 FDG PET/CT for initial staging in breast cancer with clinically negative axillary nodes.
Jeong YJ; Kang DY; Yoon HJ; Son HJ
Breast Cancer Res Treat; 2014 May; 145(1):137-42. PubMed ID: 24682676
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.
You S; Kang DK; Jung YS; An YS; Jeon GS; Kim TH
Br J Radiol; 2015 Aug; 88(1052):20150143. PubMed ID: 26110204
[TBL] [Abstract][Full Text] [Related]
19. The value of primary tumor (18)F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis.
Jung NY; Kim SH; Kang BJ; Park SY; Chung MH
Breast Cancer; 2016 Sep; 23(5):712-7. PubMed ID: 26219608
[TBL] [Abstract][Full Text] [Related]
20. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]